Current Best Practice in Interventional Cardiology E-Book

• Herausgeber: John Wiley & Sons
• Kategorie: Fachliteratur
• Sprache: Englisch

Seitenzahl: 538

Veröffentlichungsjahr: 2011

Beschreibung

Current Best Practice in Interventional Cardiology addresses the questions which challenge clinicians involved with interventional procedures. Helpfully organized into four sections, the text addresses; coronary artery disease, non-coronary interventions, left ventricular failure and the latest advances in imaging technologies, and provides authoritative guidance on the current recommendations for best practice. Containing contributions from an international team of opinion leaders, this new book reviews the key advances in equipment, techniques and therapeutics and is an accessible reference for all hospital-based specialists.

Leseprobe

Contents

List of Contributors

Preface

Part I Coronary Artery Disease

1 Acute Coronary Syndromes

ST-Segment Elevation Myocardial Infarction

Non-ST-Elevation Acute Coronary Syndromes

2 Modern Coronary Stenting

First-Generation Drug-Eluting Stents

New Generation of Drug-Eluting Stents

Drug-Eluting Stents in the Treatment of Intermediate Lesions

Comparison of Modern PCI with Bypass Surgery

Modern Passive Stents (BMS) and Bioactive Stents

3 Chronic Total Occlusion

Definition

Prevalence

Pathologic Features

Clinical Presentation

Rationale and Indications for Recanalization

Left Ventricular Function after PCI

Patient Selection

Complications

Outcome and Trends

Recent Developments: Retrograde Approach

Long-Term Prognosis: Restenosis Rate and Late Patency

PCI of CTO in SVG

New Devices for CTO Revascularization

Technical Considerations

Future Trends

4 Nonrevascularization Therapy

Shock-Wave Therapy

Spinal Cord Stimulation

Coronary Sinus Restriction

Part II Noncoronary Interventions

5 Transcatheter Aortic Valve Implantation

Edwards-Sapien (Previously Cribier–Edwards) Prosthesis

Medtronic Corevalve Revalving System

Other Competing Technologies

Current Indications and Patient Selection

Conclusions

6 Patent Foramen Ovale Closure

What is a Patent Foramen Ovale?

Prevalence of PFOs

Medical Interest in PFOs

Clinical Assessment of PFO Risk

Percutaneous PFO Closure

Technique

Complications

Results

Outlook

7 Closure of Atrial and Ventricular Septal Defects in Adults

Atrial Septal Defects

Ventricular Septal Defects

Conclusions

8 Carotid Artery Stenting

Historical Perspective

Multicenter Clinical Trials

Indications and Contraindications of Carotid Stenting

Role of Carotid Angiography in Patient Selection

Patient and Lesion Selection

Expected Results with Experienced Operators and Appropriate Patient Selection

Technical Considerations

Causes of Stroke Prior to Treating the Lesion

Postprocedure Management

Special Considerations

Future Directions

9 Alcohol Ablation of Hypertrophic Cardiomyopathy

Clinical Picture of Hypertrophic Cardiomyopathy

Therapeutic Strategies in Hypertrophic Cardiomyopathy

Technique of Alcohol Ablation of the Septum

Complications of Alcohol Ablation

Perspectives

Part III Treatment of Left Ventricular Failure

10 Biventricular Pacing

Overview of Cardiac Resynchronization Therapy

Current Indications for CRT

Defining Response to CRT

Optimization of Patient Selection

Optimizing Lead Position

Optimizing Device Programming

Conclusions

11 Percutaneous Left Ventricular Assist Devices

The Tandem Heart Percutaneous Left Ventricular Assist Device

Impella Recover LP PLVAD

Left Ventricular Assist Devices for Postmyocardial Infarction Complicated with Cardiogenic Shock

Percutaneous Left Ventricular Assist Devices to Support High-Risk Percutaneous Coronary Interventions

Conclusion

12 Treatment of Left Ventricular Failure

Drug Therapy with Cardiac Resynchronization Therapy

Drug Therapy with Percutaneous Assist Devices

Part IV Cardiovascular Imaging

13 Computed Tomography for Screening and Follow-up

CT Technology

Coronary CT Angiography for the Detection of Stenoses

Future Perspectives

14 Magnetic Resonance for Functional Testing and Interventional Guidance

System Requirements Personnel Qualifications and Safety

Ventricular Volumes and Function

Scar Detection/Assessment of Viability

Ischemia Detection

Interventional Guidance

Clinical Applications

Conclusion

15 Optical Coherence Tomography for Coronary Imaging

Atherosclerotic Plaque Characterization and Vulnerable Plaque Detection

Guidance of Percutaneous Coronary Intervention

Stent Deployment Characteristics and Vessel Injury Post Stent Implantation

Stent Strut Coverage Post Stent Implantation

Conclusion

16 Intravascular Ultrasound

Drug-Eluting Stents

Drug-Eluting Balloons

Beyond Gray-Scale IVUS

Index

This edition first published 2010 © 2010 by Blackwell Publishing Ltd

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Current best practice in interventional cardiology / edited by Bernhard Meier.

p.; cm.

Includes bibliographical references.

ISBN 978-1-4051-8255-3

1. Heart-Surgery. 2. Heart-Diseases-Treatment. 3. Heart-Interventional radiology.

I. Meier, Bernhard, M.D.

[DNLM: 1. Heart Diseases-surgery. 2. Cardiovascular Diseases-diagnosis. 3. Diagnostic Imaging-methods.

4. Vascular Diseases-surgery. WG 169 C97517 2009]

RD598.C84 2009

617.4𠈲12-dc22

2009014017

ISBN: 9781405182553

List of Contributors

Preface

PART I

CoronaryArteryDisease

CHAPTER 1

Acute Coronary Syndromes

Pierre-Frédéric Keller

Marco Roffi

Division of Cardiology, University Hospital of Geneva, Geneva, Switzerland

Chapter Overview

Acute coronary syndromes (ACS) are the acute manifestation of atherosclerotic coronary artery disease. Based on different presentations and management, patients are classified into non-ST-segment elevation ACS (NSTE-ACS) and ST-segment elevation myocardial infarction (STEMI).In western countries, NSTE-ACS is more frequent than STEMI.Even if the short-term prognosis (30 days) for NSTE-ACS is more favorable than for STEMI, the long-term prognosis is similar or even worse.Early invasive strategy is the management of choice in patients with NSTE-ACS, particularly in high-risk subgroups.Primary percutaneous coronary intervention (PCI) is the treatment of choice for STEMI. Facilitated PCI is of no additional benefit.The reduction of door-to-balloon time in primary PCI is critical for improved outcomes in STEMI patients.If fibrinolytic therapy is administered in STEMI, then patients should be routinely transferred for immediate coronary angiography, and if needed, percutaneous revascularization.High-risk ACS patients (eg, elderly patients, those in cardiogenic shock) have the greatest benefit from PCI.Antithrombotic therapy in ACS is getting more and more complex. The wide spectrum of antiplatelet agents and anticoagulants requires a careful weighing of ischemic and bleeding risks in each individual patient.

ST-Segment Elevation Myocardial Infarction

The term acute coronary syndrome (ACS) has emerged as useful tool to describe the clinical correlate of acute myocardial ischemia. ST-segment elevation (STE) ACS includes patients with typical and prolonged chest pain and persistent STE on the ECG. In this setting, patients will almost invariably develop a myocardial infarction (MI), categorized as ST-segment elevation myocardial infarction (STEMI). The term non-ST-segment (NSTE) ACS refers to patients with signs or symptoms suggestive of myocardial ischemia in the absence of significant and persistent STE on ECG. According to whether the patient has at presentation, or will develop in the hours following admission, laboratory evidence of myocardial necrosis or not, the working diagnosis of NSTE-ACS will be further specified as NSTE-MI or unstable angina.

Recently, MI was redefined in a consensus document [1]. The 99th percentile of the upper reference limit (URL) of troponin was designated as the cut-off for the diagnosis. By arbitrary convention, a percutaneous coronary intervention (PCI)-related MI and coronary artery bypass grafting (CABG)-related MI were defined by an increase in cardiac enzymes more than three and five times the 99th percentile URL, respectively. The application of this definition will undoubtedly increase the number ofevents detected in the ACS and the revascularization setting. The impact on public health as well as at the clinical trial level of the new MI definition cannot be fully foreseen.

The extent of cellular compromise in STEMI is proportional to the size of the territory supplied by the affected vessel and to the ischemic length of time. Therefore a quick and sustained restoration of normal blood flow in the infarct-related artery is crucial to salvage myocardium and improve survival.

Primary PCI Versus Thrombolytic Therapy

Primary percutaneous coronary intervention became increasingly popular in the early 1990s. Evidence favoring this strategy in comparison with thrombolytic therapy is substantiated by a metaanalysis of 23 randomized trials demonstrating that PCI more efficaciously reduced mortality, nonfatal reinfarction, and stroke (Fig. 1.1) [2]. The advantage of primary PCI over thrombolysis was independent of the type of thrombolytic agent used, and was also present for patients who were transferred from one institution to another for the performance of the procedure. Therefore, primary PCI is now considered the reperfusion therapy of choice by all the guidelines [3,4]. With respect to bleeding complications, a recent meta-analysis demonstrated that the incidence of major bleeding complications was lower in patients treated with primary PCI than in those undergoing thrombolytic therapy [2]. In particular intracranial hemorrhage, the most feared bleeding complication, was encountered in up to 1% of patients treated with fibrinolytic therapy and in only 0.05% of primary PCI patients. The algorithm for treatment of patients admitted for a STEMI is presented in Fig. 1.2 [5].

Figure 1.1 Short-term clinical outcomes of patients in 23 randomized trials of primary PCI versus thrombolysis. (Reproduced with permission from [2] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.)

Figure 1.2 Algorithm for revascularization in STEMI patients with less than 12 hours from symptom onset according to the 2005 ESC guideline for PCI. (Reproduced with permission [5] from Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–847.)

Advantages of Primary PCI

More than 90% of patients treated by primary PCI achieve normal flow (thrombosis in myocardial infarction [TIMI] grade flow 3) at the end of the intervention, while only 65% of patients treated by thrombolytic therapy benefit from this degree of reperfusion (Table 1.1) [6–8]. In addition, thrombolyis is characterized by a rapidly decreased efficacy after 2 hours of symptom onset (Fig. 1.3) [9]. There is a close relationship between the quality of coronary flow obtained after reperfu-sion therapy and mortality, and the prognosis of patients in whom flow normalization is not achieved is similar to that of patients with persistent vessel occlusion. The classification of TIMI myocar-dial blush grade allows an estimate of the tissue-level perfusion (Table 1.1). A critical link between lower TIMI myocardial blush grade, expression of a microcirculatory compromise, and mortality has been demonstrated in patients with normal epicardial flow following reperfusion therapy [10]. The improvement of clinical outcomes with primary PCI versus thrombolysis is also the consequence of a lower rate of reocclusion (0–6%). Accordingly, with thrombolytic therapy, reocclusion may occur in over 10% of cases even among patients presenting within the first 2 hours of symptom onset.

Mechanical complications of STEMI, such as acute mitral regurgitation and ventricular septal defect, were reduced by 86% by primary PCI compared with thrombolytic therapy in a meta-analysis of the GUSTO-1 and PAMI trials [11]. Free wall rupture was also significantly reduced by primary PCI [12]. Finally, primary PCI may allow earlier discharge (2–3 days following PCI versus 7 days following fibrinolytic therapy for uncomplicated courses).

Table 1.1 TIMI Classication of Coronary Flow and Perfusion

Flow Grade ClassificationTIMI Flow GradeDefinition0No antegrade flow beyond the point of occlusion.1Faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete.2Delayed or sluggish antegrade flow with complete filling of the distal territory.3Normal flow that fills the distal coronary bed completely.Perfusion Grade ClassificationPerfusion GradeDefinition0Minimal or no myocardial blush is seen.1Dye stains the myocardium; this stain persists on the next injection.2Dye enters the myocardium but washes out slowly so that the dye is strongly persistent at the end of the injection.3There is normal entrance and exit of the dye in the myocardium so that the dye is mildly persistent at the end of the injection.

Adapted with permission from [7] Gibson CM, Schomig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004;109:3096–3105; and [8] Schömig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865–2872.

Figure 1.3 Time delays to thrombolysis in STEMI and the absolute reduction in 35-day mortality. (Reproduced with permission from [9] Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771–775.)

Decreasing the Time to Reperfusion in Primary PCI

The survival benefit of reperfusion associated with thrombolytic therapy shrinks with increasing delay in the administration of the agent. For stable patients undergoing primary PCI, no association between symptom-onset-to-balloon time and mortality was observed in the U.S. NRMI registry [13]. In contrast, a significant increase in mortality was detected for patients with a door-to-balloon-time greater than 2 hours [14]. Therefore, the findings of primary PCI trials may be only applicable to hospitals with established primary PCI programs, experienced teams of operators, and a sufficient volume of interventions. Indeed, an analysis of the NRMI-2 registry demonstrated that hospitals with less than 12 primary PCIs per year have a higher rate of mortality than those with more than 33 primary PCIs per year [13]. Useful tools to decrease the door-to-balloon time are described in Table 1.2 [15].

Challenging Groups of Patients

Concomitant High-Grade Non-Culprit Lesions

The timing of revascularization of severe non-culprit lesion treatment in patients with multivessel

Table 1.2 Strategies to Reduce the Door-to-Balloon Time in Primary PCI

Emergency medicine physicians activate the catheterization laboratory (mean reduction in door-to-balloon time, 8.2 minutes)Having a single call to a central page operator activate the laboratory (13.8 minutes)Having the emergency department activate the catheterization laboratory while the patient is en route to the hospital (15.4 minutes)Expecting staff to arrive in the catheterization laboratory within 20 minutes after being paged (vs. >30 minutes) (19.3 minutes)Having an attending cardiologist always on site (14.6 minutes),Having staff in the emergency department and the catheterization laboratory use real-time data feedback (8.6 minutes).

From [15] Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med. 2006;355:2308–2320.

disease undergoing primary PCI has long been debated. Multivessel PCI in stable STEMI patients was found to be an independent predictor of major adverse cardiac events (MACE) at 1 year [16]. However, a recent study suggested that systematic revascularization of multivessel disease at the time of primary PCI in contrast to ischemia-driven revascularization may be of advantage because incomplete revascularization was found to be a strong and independent risk predictor for death and MACE [17]. Another study supported the notion that complete revascularization improved clinical outcomes in STEMI patients with multivessel disease [18]. Accordingly, the study showed a significant lower rate of recurrent ischemic events and acute heart failure during the indexed hospitalization. Nevertheless, current American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that PCI of the non-infarct artery should be avoided in the acute setting in patients without hemodynamic instability [19].

Cardiogenic Shock

The incidence of cardiogenic shock in acute MI patients is in decline, accounting for approximately 6% of all cases [20]. As the result of the increasing use of primary PCI, the shock-related mortality has decreased. Accordingly, a U.S. analysis showed mortality rates in shock of 60% in 1995 and 48% in 2004, while the corresponding primary PCI rates were 27% to 54% [21]. In the SHOCK trial, early revascularization was associated with a significant survival advantage [22]. In the study, approximately two-thirds of patients in the invasive arm were revascularized by PCI and one-third by CABG surgery. Thrombolysis was administered in 63% of patients allocated to the medical stabilization arm. Early revascularization is strongly recommended for shock patients younger than 75 years. In older patients, revascularization may be considered in selected patients [23].

In the last two decades, hemodynamic support devices have been developed to limit end-organ failure in the setting of cardiogenic shock. The intraaortic balloon pump (IABP) is the most commonly used mechanical support device. Percutaneous left atrial-to-femoral arterial bypass assistance, and more recently the Impella Recover microaxial left ventricular and/or right ventricular assist device, have been developed to increase cardiac output. However, no randomized clinical data exist to support the benefit of this device. Percutaneous cardiopulmonary bypass support using extracorporeal membrane oxygenation (ECMO) can be used in cardiogenic shock for a longer period of time than the other devices just described. However, while ECMO has excellent oxygenation properties, it provides only limited cardiac output support.

Elderly Patients